Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2018 | Research

Effect of RSK4 on biological characteristics of colorectal cancer

Authors: Qingqing Ye, Xuan Wang, Min Jin, Meng Wang, Yan Hu, Shihu Yu, Yonghua Yang, Jiyuan Yang, Jun Cai

Published in: World Journal of Surgical Oncology | Issue 1/2018

Abstract

Background

This study aimed to investigate the expression of P90 Ribosomal Protein S6 kinase 4 (RSK4) in colorectal cancer cells and its biological function.

Methods

We selected early SW480 and HCT116 colorectal cancer cell lines, using Lipofectamine™ 2000 transfection reagent carrying RSK4 gene transfected into cells to establish the colorectal cancer cell lines with high expression of RSK4. RT-PCR and western blot (WB) analysis confirmed RSK4 expression in SW480 and HCT116 cancer cell lines. We used methylthiazoltetrazolium (MTT) assay and flow cytometry to detect the proliferation of colorectal cancer cells. After transfection of RSK4, the effect of RSK4 on the RNA levels associated with epithelial–mesenchymal transition (EMT) of colorectal cancer cells was analyzed by real-time fluorescence quantitative PCR and the expression of EMT-related protein was detected by WB analysis.

Results

After transfection of RSK4 overexpression, the MTT assay detected that RSK4 could significantly inhibit the growth of colorectal cancer cells in vitro; flow cytometry detected that S-phase cells decreased significantly, and G0/1 cells increased significantly (P < 0.05). The invasion ability of SW480 and HCT116 cells transfected with RSK4 was markedly lower than that in the control group, and the difference was statistically significant (P < 0.05). Fluorescent quantitative PCR and WB analysis showed that the expression of EMT-associated molecular E-cadherin was remarkably increased and the expression of Snail was significantly decreased (P < 0.01).

Conclusion

RSK4 gene in colorectal cancer cell lines with low expression of RSK4 after transfection can inhibit the growth and invasion of tumor cells. RSK4 gene may inhibit EMT and inhibit metastasis of colorectal cancer cells, may be a potential tumor suppressor gene and inhibit tumor distant metastasis, and may provide the biological basis for new therapeutic targets.

Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J. 2012;441:553–69. https://doi.org/10.1042/bj20110289.CrossRefPubMed

Fan L, et al. Ribosomal s6 protein kinase 4: a prognostic factor for renal cell carcinoma. Br J Cancer. 2013;109:1137–46. https://doi.org/10.1038/bjc.2013.463.CrossRefPubMedPubMedCentral

Lara R, et al. An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene. 2011;30:3513–21. https://doi.org/10.1038/onc.2011.61.CrossRefPubMed

Vesely P, Rovensky Yu A, Slavnaya IL. Cinemicrographic analysis of migration of normal and neoplastic rat cells seeded upon the grooved surface. Folia Biol. 1981;27:81–90.

Yang HW, et al. Effects of breast cancer cells stably overexpressing RSK4 on growth of transplanted human breast cancer in severe combined immunodeficiency mice. Zhonghua Yi Xue Za Zhi. 2012;92:1845–8.PubMed

Zhu J, et al. RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells. Oncol Rep. 2015;34:3156–62. https://doi.org/10.3892/or.2015.4291.CrossRefPubMed

Jiang Y, et al. Aberrant expression of RSK4 in breast cancer and its role in the regulation of tumorigenicity. Int J Mol Med. 2017;40:883–90. https://doi.org/10.3892/ijmm.2017.3069.CrossRefPubMed

Thakur A, et al. Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol Cancer Res. 2007;5:171–81. https://doi.org/10.1158/1541-7786.mcr-06-0071.CrossRefPubMed

Dewdney SB, et al. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res. 2011;17:2120–9. https://doi.org/10.1158/1078-0432.ccr-10-2668.CrossRefPubMedPubMedCentral

10.

Sun Y, et al. Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4. Oncogene. 2013;32:1794–810. https://doi.org/10.1038/onc.2012.200.CrossRefPubMed

11.

Cai J, et al. Low expression of RSK4 predicts poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2014;7:4959–70.PubMedPubMedCentral

12.

Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. https://doi.org/10.3322/caac.21338.CrossRefPubMed

13.

Van Cutsem E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17. https://doi.org/10.1056/NEJMoa0805019.CrossRefPubMed

14.

Yang JC, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–34. https://doi.org/10.1056/NEJMoa021491.CrossRefPubMedPubMedCentral

15.

Mishima H, et al. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE study). Jpn J Clin Oncol. 2012;42:134–8. https://doi.org/10.1093/jjco/hyr180.CrossRefPubMed

16.

Petrelli F, et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013;12:145–51. https://doi.org/10.1016/j.clcc.2013.04.006.CrossRefPubMed

17.

Heinemann V, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75. https://doi.org/10.1016/s1470-2045(14)70330-4.CrossRefPubMed

18.

Sadanandam A, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19:619–25. https://doi.org/10.1038/nm.3175.CrossRefPubMedPubMedCentral

19.

Dummler BA, et al. Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem. 2005;280:13304–14. https://doi.org/10.1074/jbc.M408194200.CrossRefPubMed

20.

Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013;123:2551–63. https://doi.org/10.1172/jci66343.CrossRefPubMedPubMedCentral

21.

Lopez-Vicente L, et al. Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors. Clin Cancer Res. 2009;15:4546–53. https://doi.org/10.1158/1078-0432.ccr-08-3159.CrossRefPubMed

22.

Cai J, et al. Down-regulation of long noncoding RNA RP11-713B9.1 contributes to the cell viability in nonsmall cell lung cancer (NSCLC). Mol Med Rep. 2017;16:3694–700. https://doi.org/10.3892/mmr.2017.7026.CrossRefPubMed

23.

Rafiee M, et al. Down-regulation of ribosomal S6 kinase RPS6KA6 in acute myeloid leukemia patients. Cell J. 2016;18:159–64.PubMedPubMedCentral

24.

Niskakoski A, et al. Epigenetic analysis of sporadic and lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Epigenetics. 2014;9:1577–87. https://doi.org/10.4161/15592294.2014.983374.CrossRefPubMed

Title: Effect of RSK4 on biological characteristics of colorectal cancer
Authors: Qingqing Ye
Xuan Wang
Min Jin
Meng Wang
Yan Hu
Shihu Yu
Yonghua Yang
Jiyuan Yang
Jun Cai
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2018
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-018-1474-7

At a glance: The STEP trials

Springer Medicine

Effect of RSK4 on biological characteristics of colorectal cancer

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials

Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study

A study on the value of narrow-band imaging (NBI) for the general investigation of a high-risk population of nasopharyngeal carcinoma (NPC)

Concurrent presentation of an intraductal tubulopapillary neoplasm and intraductal papillary mucinous neoplasm in the branch duct of the pancreas, with a superior mesenteric artery aneurysm: a case report

A quest for sphincter-saving surgery in ultralow rectal tumours—a single-centre cohort study

Laparoscopic right-sided colon resection for colon cancer—has the control group so far been chosen correctly?